S&P 500 climbs, but Nvidia slip keeps lid on gains
DUBLIN - Morgan Stanley & Co. LLC disclosed on Wednesday its trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares as required under Irish takeover rules.
According to the regulatory filing submitted to the Irish Takeover Panel, Morgan Stanley, acting as an exempt principal trader with recognized intermediary status, purchased 142,787 ordinary shares of Avadel Pharmaceuticals on November 4, 2025, at prices ranging from $18.78 to $18.95 per share.
The filing also revealed that Morgan Stanley sold 146,176 Avadel shares on the same day, with transaction prices between $18.78 and $18.95 per share.
The disclosure was made in compliance with Rule 38.5(a) of the Irish Takeover Panel Act, which requires connected exempt principal traders to report dealings in relevant securities of companies involved in takeover situations.
Morgan Stanley confirmed in the filing that it is connected to Avadel Pharmaceuticals in relation to the disclosed transactions. The filing indicated no cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were conducted in Avadel securities during this period.
The disclosure, submitted as a regulatory news service announcement, contained no information about any indemnity arrangements or agreements relating to options or derivatives involving Avadel shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.